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Background: We previously showed that stool samples of pre-adolescent and adolescent US children diagnosed
with diarrhea-predominant IBS (IBS-D) had different compositions of microbiota and metabolites compared to
healthy age-matched controls. Here we explored whether observed fecal microbiota and metabolite differences
between these two adolescent populations can be used to discriminate between IBS and health.
Findings: We constructed individual microbiota- and metabolite-based sample classification models based on the
partial least squares multivariate analysis and then applied a Bayesian approach to integrate individual models into
a single classifier. The resulting combined classification achieved 84 % accuracy of correct sample group assignment
and 86 % prediction for IBS-D in cross-validation tests. The performance of the cumulative classification model was
further validated by the de novo analysis of stool samples from a small independent IBS-D cohort.
Conclusion: High-throughput microbial and metabolite profiling of subject stool samples can be used to facilitate
IBS diagnosis.
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Irritable bowel syndrome (IBS) is one of the most common
disorders of the human gastrointestinal system affecting
approximately 10-20 % of the population worldwide [1].
This syndrome affects young children, adolescents, and
adults, with higher prevalence in adolescence [2]. IBS can
be manifested by varied symptoms that include abdominal
pain, changes in bowel habit, bloating and excessive flatus
without visible damage to the intestinal mucosa, or high-
level inflammation. Several different subtypes of IBS are
recognized including diarrhea-predominant (IBS-D),
constipation-predominant, mixed-type, and unsubtyped
IBS [1, 3].
Proposed causes of IBS include increased intestinal
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intestine, acute bacterial gastroenteritis, and altered im-
mune response of the host [1, 3]. Several of these causes
are linked to the functionality of human intestinal micro-
biota [4], and a number of recent studies have provided
emerging evidence of gut microbiota alterations in IBS
[5–8]. Gut microbes can affect the host directly through
host-microbial interactions or indirectly through the
transformation and production of organic compounds
that are released into the intestinal lumen [9]. Thus, differ-
ences in microbial communities between healthy individ-
uals and those with IBS can manifest themselves as
disparities in luminal metabolite profiles, a hypothesis
supported by several reports [10–12].
The variety of symptoms that can be associated with
IBS and the lack of readily observable intestinal patho-
physiology make the diagnosis of this syndrome chal-
lenging. Rome criteria serve as the current standard
diagnostic tool in clinical trials [1, 3], while differente is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Schematic overview of the classification model generation.
Pink and green points represent individual kIBS and kHLT samples,
respectively, distributed in the simulated T-vs-Torthogonal PLS ordination
space. Blue point represents an unknown sample that is classified by
the PLS-DA models. M and C denote overall microbiota- and
metabolite-based classification models, respectively; G is the group
identifier; b0…n are numerical parameters and m1…n and c1…p are
values of specific microbes and metabolites, respectively. See statistical
data analyses section for the definitions of Bayesian model terms
and parameters
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gen breath tests are sometimes used in the clinic to rule
out alternative causes [3, 4, 13]. Because of symptom
overlap with other disorders, IBS can often be misdiag-
nosed, and IBS patients undergo unnecessary invasive
tests such as colonoscopy [14]. Therefore, finding add-
itional criteria to define IBS would advance its diagnosis,
lower medical costs, and improve patient outcomes [1].
In previous reports, we compared the fecal microbiota
and metabolites of healthy pre-adolescent and adolescent
children to those from children diagnosed with diarrhea-
predominant IBS [6, 12, 15]. The fecal samples were ob-
tained from 22 healthy children (average age = 12.6 years)
and from 22 age-matched children with IBS-D (average
age = 13.2 years) of both genders. Diagnosis of the IBS,
inclusion and exclusion criteria, and stool collection pro-
cedure were described previously [6]. Phylogenetic Micro-
biota Array was used to obtain quantitative microbial
phylotype and genus abundance values from all collected
fecal samples [16]. Proton (H1) nuclear magnetic reson-
ance (NMR) spectrometry was employed to obtain spec-
tral bin values and quantified metabolite levels measured
in the same set of stools [12]. Specific differences in the
fecal levels of several microbial genera and metabolites
were observed between IBS and healthy cohorts. We hy-
pothesized that these microbiota and metabolite data can
be subjected to a multivariate discriminant analysis to
distinguish between IBS and healthy gut. Multivariate dis-
crimination methods such as partial least squares discrim-
inant analysis (PLS-DA) are very effective at identifying
dataset patterns that differentiate samples between differ-
ent groups. These techniques take into consideration the
known group assignment (e.g., IBS-vs-health) for each
sample and aim to find a combination of measured vari-
ables (e.g., specific microbial abundances or metabolite
levels) that can cumulatively separate all or most samples
from one group from all or most samples from another
group. Indeed, our previous studies revealed that inde-
pendent microbial and metabolite profiling of fresh stool
samples collected from IBS-D and healthy pre-adolescent
and adolescent children can separate these samples in
the PLS ordination space with good statistical signifi-
cance (p < 0.02) [12, 15]. Techniques such as PLS-DA
also offer an intriguing opportunity to classify unknown
samples based on the previously constructed model of
sample group separation (e.g., IBS-vs-health). This can
be used to supplement disease diagnosis in clinical
practice. We have thus conducted PLS-DA analyses of
fecal microbiota and metabolite datasets obtained pre-
viously for the IBS-D (denoted kIBS) and healthy (de-
noted kHLT) child cohorts [6, 12, 15]. The overall
procedure is depicted in Fig. 1. Full microbial and
metabolite datasets used to construct PLS-DA models
are provided in Additional file 1. Detailed descriptionof methods and statistical procedures is available in
Additional file 2.
We first generated individual sample classification models
based separately on the microbiota and metabolite profiles
of the examined samples (Additional file 3 contains class
assignment probabilities for each sample). Our PLS-DA
model based on the microbial genus abundances in kIBS
and kHLT samples achieved 79.5 % accuracy of correct
sample classification (sensitivity—72.7 %, specificity—86.4 %,
predictive value for IBS (PVIBS) = 84.2 %) [15]. The
metabolite-based PLS-DA model for the same set of sam-
ples attained 81.8 % accuracy of sample group assignment
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While each individual classification model displayed re-
spectable performance parameters, we hypothesized that
combining multiple sample classifications into a joint classi-
fier/predictor can improve prediction accuracy and model
robustness. To that goal, we employed an integrative Bayes-
ian approach to combine separate PLS-DA models (one
based on metabolite measurements and another based on
genus abundance values) into a single classifier as shown in
Fig. 1. Combining two models significantly improved
our group assignment accuracy and confidence (Fig. 2a):
the resulting integrative model achieved an 84.1 % accur-
acy level with an average 87.8 % confidence of correct
sample classification (sensitivity—81.8 %, specificity—86.4 %,
PVIBS = 85.7 %). The diagnostic accuracy of the integrative
PLS-DA model compared favorably to other IBS diagnostic
tools and biomarkers [17]. The combination of the cumula-
tive model’s high positive likelihood ratio (6.02; describes
the likelihood of an individual having the disease if the diag-
nostic test is positive) and low negative likelihood ratio
(0.21; describes the likelihood of an individual having the
disease if the test is negative) would rank the cumulative
genus-metabolite PLS-DA model in the top 3 individual
diagnostic tests for IBS [17]. Similar improvement in
sample classification was also observed for the com-
bined model based on PLS-DA analyses of the fullFig. 2 Improvement of sample classification based on the integration of micr
are shown as provided by the microbial genus abundance-based PLS-DA
combined Bayesian model (bottom row). Each column represents a uniqu
according to the group assignment confidence based on the gradient as
for each model are indicated at the right of the figure. b Application of t
c Density distribution plots of PDI values for IBS-D and healthy adolescent sam
compute PDI values. The X axis shows the range of PDI values; the Y axis repr
axis. PDI values for individual kIBS and kHLT samples are shown on the plots a
operating characteristic analysis of PLS-DA models (left panel) and patient disc
discrimination ability of each model; higher value equals better discriminationNMR spectral bin data and microbial phylotype values
(see Additional file 4).
To further assess Bayesian classification model per-
formance, the model was applied to the microarray and
NMR datasets obtained from fecal samples of four newly
recruited IBS-D adolescent patients. Even though indi-
vidual PLS-DA models were unable to grade all four
samples as IBS, the combined microbiota-metabolite
PLS-DA model classified fecal samples correctly as IBS
type for all new participants (Fig. 2b). The receiver oper-
ating characteristic (ROC) analysis presented in Fig. 2d
was used to assess the expected performance of PLS-DA
models as a clinical diagnostic test. Area under the ROC
curve (AUC) values were 0.87, 0.88, and 0.93 for metab-
olite-, genus-, and integrated metabolite-genus-based
PLS-DA classification, respectively, indicating that fecal
metabolite-genus PLS-DA classifiers can be expected to
perform very well as diagnostic tools. Similar perform-
ance characteristics were evident from the ROC ana-
lysis of spectral binned-microbial phylotype dataset (see
Additional file 4).
To facilitate the application of fecal microbiota- and
metabolite-based sample classification in the clinical set-
ting, we also calculated an IBS-vs-health patient discrim-
ination index (PDI) following a recently described
strategy [18]. To compute the PDI, we first identified theobiota- and metabolite-based PLS-DA models. a Sample classifications
model (top row), metabolite-based PLS-DA model (middle row), and
e sample from IBS and healthy sets as shown. Each square is colored
shown in the legend. Average assignment accuracy and confidence
he Bayesian integration model to a set of four new IBS-D samples.
ples. Top three discriminating genera and metabolites were used to
esents the density (frequency) of PDI values at each position along the X
s discrete points. Blue points represent new IBS-D samples. d Receiver
rimination indices (right panel). AUC area under the curve (represents the
), G genus, M metabolite
Shankar et al. Microbiome  (2015) 3:73 Page 4 of 5top discriminating genera and equal number of discrim-
inating metabolites based on the ranks of their PLS
weights. We then compared the values of each discrim-
inating variable in a sample to the median value of that
variable among all 44 samples of the training dataset.
The sum of log2 of the ratio between a variable value
and its median for discriminating variables was taken to
produce the PDI. The complete calculation formula is
provided in Additional file 2. The index was designed so
that a PDI above zero would indicate that the unknown
sample is more likely to be from an IBS-D patient,
whereas a PDI value below zero would correspond to
samples from healthy individuals. Figure 2d presents the
ROC analysis of expected diagnostic performance of dif-
ferent PDIs based on the number of top discriminating
variables used. The ROC analysis indicated that inclu-
sion of the top three genera (Parasporobacterium, Oxa-
lobacter, and Enterobacter) and top three metabolites
(formate, pyruvate, and glucose) in PDI presented the
best discriminating power (highest AUC value) com-
pared to other choices. Figure 2c shows the density dis-
tributions of the top three “genera + metabolites” PDI
values for the kIBS and kHLT samples. While the dis-
criminatory power of PDI is lower than that of the
Bayesian classification model described above, the me-
dian PDI was nevertheless significantly different between
healthy and IBS groups (3.0 and −1.7 median PDI for
kIBS and kHLT groups, respectively; p < 0.001 based on
Mood’s median test of significance). We also calculated
PDI values for new IBS-D samples. Three of the four
samples had positive PDI values (2.6, 2.0, and 1.8; PDI > 0
indicates higher likelihood of IBS diagnosis) and one sam-
ple had a negative PDI (−1.1, see Fig. 2c). These results in-
dicate that PDI can be used to facilitate classification of
patients with IBS-D.
Because the diagnosis of IBS still presents several chal-
lenges [14], additional non-subjective diagnostic tools can
significantly facilitate clinical assessment of a patient. The
combined metabolite- and microbiota-based IBS-vs-health
classification model described above does not rely on the
identification of a single unique biomarker of the disease;
rather, it assembles a set of recognized fecal microbial and
metabolite differences that are used jointly to confidently
distinguish between IBS-D and health. The values of these
microbial taxons and metabolites may or may not correl-
ate to one another among samples, but all provide good
discrimination between two analyzed cohorts. This ap-
proach of relying on a set of variables makes the model
robust and able to classify correctly even some outlier
samples. Additionally, the model can reveal the individual
variables (microbial taxa and metabolites) that contribute
most to the IBS-vs-health discrimination; presumably,
these are important in the etiology of the disease. In our
models, the top discriminating genera includedParasporobacterium, Oxalobacter, and Enterobacter; the
top discriminating metabolites were formate, pyruvate,
glucose, lysine, and tyrosine (see Additional file 5). Previ-
ously conducted statistical tests also indicated that the
levels of these genera and metabolites were significantly
different between fecal samples from healthy children and
children with IBS [6, 12]. While very little information is
currently available for the discriminating microbial gen-
era, the higher levels of several amino acids including
lysine and tyrosine point to an increased proteolysis in
IBS-D. At the same time, increased levels of carbohy-
drate degradation intermediates such as glucose in the
stools of IBS-D children are likely indicators of the in-
complete fermentation process in the gut of these sub-
jects [12]. This finding is consistent with our previously
revealed loss of microbe-microbe and microbe-
metabolite associations in this cohort of IBS children
[12, 15].
While the patient’s symptom evaluation will undoubt-
edly remain a critical part of IBS diagnosis, the ability to
utilize quantifiable measurements of the components
within the gut environment should facilitate the distinction
between the healthy and IBS gut. Knowledge of specific
discriminatory microbes and metabolites in the patient gut
can also assist in the choice of the most appropriate ther-
apy, for example, the selection of antimicrobial therapy,
dietary management, pre- and probiotic treatments, or the
design of personalized symbiotic mixtures in the future.
While further analyses are needed to build a generalized
fecal diagnostic model to distinguish different subtypes of
IBS from Crohn’s disease, ulcerative colitis, other gastro-
intestinal disorders, and health, we are optimistic that sim-
ultaneous fecal microbiota and metabolite profiling, a
non-intrusive, quantitative approach, may prove useful in
enhancing the management of IBS in clinical practice.Availability of supporting data
The datasets of relative microbial abundances and metab-
olite levels (abundances of 115 genera and 19 metabolites)
measured in the set of 44 fecal samples were available from
our previous studies [6, 12] and are provided in Additional
file 1. All experimentally available data were used in PLS-
DA modeling. The datasets of microbial phylotypes and
NMR spectral bins were taken from the same sources. The
datasets supporting the results of this article are available
in Additional files 2, 3, 4, and 5.Additional files
Additional file 1: Complete PLS-DA input datasets. This file contains
input datasets that were used to generate PLS-DA models. (XLSX 591 kb)
Additional file 2: Detailed methods and statistical procedures.
(PDF 126 kb)
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obtained in PLS-DA models. This table shows the class assignment
probabilities for each sample obtained in PLS-DA models. (PDF 247 kb)
Additional file 4: Improvement of sample classification based on
the integration of microbial phylotype and NMR spectral bin-based
PLS-DA models. (a). Sample classifications are shown as provided by the
microbial phylotype abundance-based PLS-DA model (top row), NMR
spectral bin-based PLS-DA model (middle row), and combined Bayesian
model (bottom row). (b). Application of the phylotype + spectral bin
Bayesian integration model to a set of four new IBS-D samples. (c). Receiver
operating characteristic analysis of the phylotype + spectral bin PLS-DA
models. (TIF 767 kb)
Additional file 5: Assigned weights for all variables applied to
generate PLS discrimination between IBS-D and healthy groups.
(PDF 38 kb)
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